 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: EGFR-TKI combined with thymosin in the treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC) improves patient outcomes

Front Oncol: EGFR-TKI combined with thymosin in the treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC) improves patient outcomes

 Last Update: 2022-02-19
 Source: Internet
 Author: User

Tags

reynolds advanced

nalgene small mouth

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, a team from Xinqiao Hospital of Chongqing Military Medical University has carried out related research, mainly to explore the efficacy and safety of EGFR-TKI combined with thymosin in the treatment of advanced non-small cell lung cancer ( NSCLC
) patients with EGFR mutations .

The results were published in the journal Frontiers in Oncology

This study retrospectively screened advanced NSCLC patients diagnosed with EGFR-sensitizing mutations from August 2008 to July 2018
.

Patients were divided into EGFR-TKI group according to treatment, and EGFR-TKI plus thymosin group was EGFR-TKI + thymosin group

This study retrospectively screened advanced NSCLC patients diagnosed with EGFR-sensitizing mutations from August 2008 to July 2018

From August 2008 to July 2018, a total of 908 patients were diagnosed with NSCLC with sensitive EGFR mutations

Clinical features

The median progression-free survival (PFS) in the EGFR-TKI + thymosin group was 14.
4 months (95% CI, 11.
7-17.
1), which was significantly better than 9.
2 months in the EGFR-TKI single-agent group (95% CI, 7.
9).
-10.
3) (HR=0.
433, 95% CI 0.
322 - 0.
582, P<0.
0001)
.

The median OS of the EGFR-TKI plus thymosin group was 29.

The median progression-free survival (PFS) in the EGFR-TKI + thymosin group was 14.

PFS and OS

The combination therapy group significantly improved patients' PFS and OS compared with the EGFR-TKI monotherapy group in most subgroups
.

The combination therapy group significantly improved patients' PFS and OS compared with the EGFR-TKI monotherapy group in most subgroups

Subgroup analysis of PFS and OS

The objective response rate (ORR) of EGFR-TKI combined with thymosin group and EGFR-TKI monotherapy group were 60.
0% and 60.
8%, respectively (P=0.
918)
.

The DCRs were 96.

The objective response rate (ORR) of EGFR-TKI combined with thymosin group and EGFR-TKI monotherapy group were 60.

The most common adverse events were rash (40.

Adverse reactions

In the EGFR-TKI monotherapy group, post-treatment CD3 + T cells decreased (P<0.
05), including CD3 + CD4 + T and CD3 + CD8 + T cell subsets (P < 0.
05)
.
However, there was no significant difference in the combination treatment group
.

Differences in T cell changes before and after treatment between the two treatment groups

In conclusion, studies have shown that EGFR-TKI combined with thymosin therapy can improve PFS and OS in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)
.

In conclusion, studies have shown that EGFR-TKI combined with thymosin therapy can improve PFS and OS in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)
.
Studies have shown that EGFR-TKI combined with thymosin therapy can improve PFS and OS in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)
.
Studies have shown that EGFR-TKI combined with thymosin therapy can improve PFS and OS in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)
.

Original source:

Feng Y, Zhu G, Lang S, Hao P, Li G, Chen F, Zhuo W, Duan Y, Zhang A, Chen Z and Sun J (2021) The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations.
Front.
Oncol.
11:659065.
doi: 10.
3389/fonc.
2021.
659065

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.